As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.
Multiple Myeloma: The Black Community, Disparities & Clinical Trials
September 21st 2023The incidence of multiple myeloma, a rare and incurable cancer of a person’s plasma cells that fight infection and disease, is more than two times higher in Black people compared to white people according to the American Cancer Society’s 2022-2024 Cancer Facts & Figures for African American/Black People.
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Rutgers Cancer Institute of New Jersey Receives Grants to Support Ongoing Oncology Research
August 4th 2023Grants totaling $1.5 million have been awarded by the New Jersey Commission on Cancer Research to several investigators at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health.
Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023
Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.
Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
What is the Role of Bispecifics in Relapsed/Refractory DLBCL?
Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy
A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL
Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel
A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel
Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL
Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Factors in Selecting Treatment for Relapsed/Refractory DLBCL
Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Overview of Relapsed/Refractory DLBCL and Management Strategies
Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma
Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations
May 26th 2023Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.
Blue Light Cystoscopy Enhances Detection of Cancer in the Bladder
May 11th 2023Saum Ghodoussipour, MD, shares how some facilities in the tri-state region including Rutgers Cancer Institute and Robert Wood Johnson University Hospital, use enhanced blue light technology with an imaging solution that better highlights cancerous tumors in the bladder.
Addressing the Challenge: Connecting Black Women with Clinical Trials
April 26th 2023Clinical trials have strikingly low rates of Black participants, even those centered on diseases that disproportionately affect Black women in particular, such as breast cancer, the most commonly diagnosed cancer and the leading cause of cancer death for this population.